Insider Transactions in Q4 2021 at Intellia Therapeutics, Inc. (NTLA)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-5.85%
|
$319,200
$133.44 P/Share
|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-4.73%
|
$307,200
$128.81 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
2,500
-54.42%
|
$297,500
$119.55 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+35.24%
|
$45,000
$18.83 P/Share
|
|
Oct 05
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
10,000
-27.69%
|
$1,300,000
$130.84 P/Share
|
|
Oct 05
2021
|
John F Crowley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.26%
|
$180,000
$18.83 P/Share
|